f(x) Immune Diagnostics, Inc. Announces New CEO
For Immediate Release:
Candler, NC, December 19, 2017 —f(x) Immune Diagnostics, Inc. today announced that its board of directors has appointed Michael Sowinski, as the Company’s new Chairman of the Board and CEO, effective immediately. “The board is delighted that Mike will lead f(x) Immune into the next stage of growth,” said Socrates Choumbakos, CFO and board secretary. “Mike has been instrumental in the success of the Company and with his leadership we are confident that our transition to providing testing kits, services, and manufacturing of fully human monoclonal antibodies against Streptococcus pneumoniae will continue to be successful.”
Sowinski is a Certified Public Accountant and graduate of the University of Central Florida. He has managed financial operations for companies of all sizes, from small family-run enterprises to Fortune 500 companies. He owns CFO Consultants, a firm that has provided tax, business valuation, and financial management services since 2006. He has been involved with the f(x) Immune since 2014.
“This is an exciting time for f(x) Immune, and I am thrilled to be taking on the CEO role,” said Sowinski. “The opportunity to lead a company like f(x) Immune and work with Joseph Martinez and Socrates Choumbakos is an honor.”
Sowinski’s appointment follows the December 2017 retirement of the company’s former CEO, Mike Hickey.
About f(x) Immune
f(x) Immune Diagnostics is an industry leader in Streptococcus pneumoniae biology and related testing. The Company provides analytical tools and services to vaccine developers, public health organizations, and researchers dedicated to reducing global morbidity and mortality from pneumococcal pneumonia and related diseases. These are largely preventable diseases that have been reduced in developed countries by use of effective vaccine programs.
The Company’s lead products are rapid, high-throughput Pneumococcal Serotyping Assays and Fully Human Monoclonal Antibody Based Reagents. The serotyping technology is used to generate pneumococcal carriage data across large populations to identify the most prevalent pathogens being carried. This data is essential to developing and deploying the most effective vaccines. The Company is also developing a broad range of assays, reagents, standards and controls to improve vaccine and drug development, manufacturing quality control and a range of other applications.
The Company recently obtained the worldwide exclusive license to provide testing kits, services, and manufacturing of fully human monoclonal antibodies against Streptococcus pneumoniae. The license was obtained from Pamlico Biopharma, Inc. and is based on patents and technologies from the Oklahoma Medical Research Foundation and Emory University.
Media Contacts: firstname.lastname@example.org
Related Links: https://fx-immune.com/